Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
Open accessThe DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Abstract
Variable regions 1 and 2 (V1/V2) of human immunodeficiency virus-1 (HIV-1) gp120 envelope glycoprotein are critical for viral evasion of antibody neutralization, and are themselves protected by extraordinary sequence diversity and N-linked glycosylation. Human antibodies such as PG9 nonetheless engage V1/V2 and neutralize 80% of HIV-1 isolates. Here we report the structure of V1/V2 in complex with PG9. V1/V2 forms a four-stranded β-sheet domain, in which sequence diversity and glycosylation are largely segregated to strand-connecting loops. PG9 recognition involves electrostatic, sequence-independent and glycan interactions: the latter account for over half the interactive surface but are of sufficiently weak affinity to avoid autoreactivity. The structures of V1/V2-directed antibodies CH04 and PGT145 indicate that they share a common mode of glycan penetration by extended anionic loops. In addition to structurally defining V1/V2, the results thus identify a paradigm of antibody recognition for highly glycosylated antigens, which-with PG9-involves a site of vulnerability comprising just two glycans and a strand.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by speci fi c antibodies, such as that seen on the surface of the HIV virion (507 -509, 594).”
From Biological roles of glycans (2017) · cites this paper as [507]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · cited 1×
“and a molecular replacement solution for the 1FD6-ZM109 data set consisting of two unbound PG9 Fab molecules per asymmetric unit was obtained using PHASE”
The PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 9,984
Nicholls, A., Sharp, K. A., & Honig, B. (1991) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340110407 · Cited by 5,240
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids
Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., Murray, L. W., Arendall, W. B., Snoeyink, J., Richardson, J. S., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm216 · Cited by 3,896
The Anatomy and Taxonomy of Protein Structure
Richardson, J. S. (1981) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60520-3 · Cited by 3,375
Research works printed but not linked: 2
- Zolla-Pazner S V2-reactive antibodies in RV144 vaccinees’ plasma AIDS Res Hum Retroviruses 27 A-21 2011
- Otwinowski, Z. & Minor, W. in Methods Enzymol. Vol. 276, 307–326 (Academic Press, 1997)
Cited by
Items 101–200 of 831
Corbett, K. S., Moin, S. M., Yassine, H. M., Cagigi, A., Kanekiyo, M., Boyoglu-Barnum, S., Myers, S. I., Tsybovsky, Y., Wheatley, A. K., Schramm, C. A., et al. (2019) · mBio · doi:10.1128/mbio.02810-18 · Cited by 154
“Eukaryotic expression of HA stem immunogens may be of particular importance because each native HA stem trimer has nine glycans and glycans have been observed to guide antibody binding by either masking certain epitopes (58, 59) or participating as part of an epitope surface (60).”
Self-citationAntibody recognition of carbohydrate epitopes
Haji‐Ghassemi, O., Blackler, R. J., Young, N. M., & Evans, S. V. (2015) · Glycobiology · doi:10.1093/glycob/cwv037 · Cited by 168
“the two glycans in gp120 allows PG9 to recognize some 80% of HIV-1 strains (McLellan et al. 2011).”
BackgroundYasmeen, A., Ringe, R. P., Derking, R., Cupo, A., Julien, J., Burton, D. R., Ward, A. B., Wilson, I. A., Sanders, R. W., Moore, J. P., et al. (2014) · Retrovirology · doi:10.1186/1742-4690-11-41 · Cited by 145
“Even when there is potential for more complex binding, simple Langmuir models have generally been fitted to the binding data [11,12,67-69].”
MethodSelf-citationStructural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1
Kong, L., Giang, E., Robbins, J. B., Stanfield, R. L., Burton, D. R., Wilson, I. A., & Law, M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202924109 · Cited by 153
Self-citationStructural vaccinology starts to deliver
Dormitzer, P. R., Grandi, G., & Rappuoli, R. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2893 · Cited by 143
Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge
Bradley, T., Pollara, J., Santra, S., Vandergrift, N., Pittala, S., Bailey‐Kellogg, C., Shen, X., Parks, R., Goodman, D. D., Eaton, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms15711 · Cited by 150
“33; HXB2 positions 154–184) was then extracted from the alignment for vaccine antigen selection.”
Self-citationSEPPA 3.0—enhanced spatial epitope prediction enabling glycoprotein antigens
Zhou, C., Chen, Z., Zhang, L., Yan, D., Mao, T., Tang, K., Qiu, T., & Cao, Z. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz413 · Cited by 138
“Also, a group of broadly neutralizing antibodies could directly target the glycan-dependent epitopes located in the V1/V2 region on HIV-1 gp120 (16).”
BackgroundNeutralizing antibodies to HIV-1 induced by immunization
McCoy, L. E., & Weiss, R. A. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20121827 · Cited by 155
“These mAbs neutralize between 70 and 80% of >150 strains of HIV tested (Walker et al., 2009) by binding preferentially to trimeric Env via the V1/2 loops of the gp120 subunit (Walker et al., 2009; McLellan et al., 2011).”
BackgroundThe Development of CD4 Binding Site Antibodies during HIV-1 Infection
Lynch, R. M., Tran, L. M., Louder, M. K., Schmidt, S. D., Cohen, M. S., DerSimonian, R., Euler, Z., Gray, E. S., Karim, S. S. A., Kirchherr, J., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00734-12 · Cited by 139
“These epitopes include the membrane-proximal region (MPER) of gp41 (6, 23, 24) and several regions on gp120, including glycan-containing regions at the base of variable regions 1 and 2 (V1V2) (3, 19, 36) and the base of V3 (25, 35) and an epitope within the CD4 binding site (CD4bs) of gp120 (9, 29, 41, 44).”
BackgroundSelf-citationIngale, J., Stano, A., Guenaga, J., Sharma, S. K., Nemazee, D. A., Zwick, M. B., & Wyatt, R. T. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.078 · Cited by 137
“We then utilized the trimerspecific, V2-directed bNAb, PGT145(McLellan et al., 2011), to confirm that, following conjugation, the quaternary variable region cap of the trimers remained intact.”
MethodSelf-citationStructure and Immune Recognition of the HIV Glycan Shield
Crispin, M., Ward, A. B., & Wilson, I. A. (2018) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-060414-034156 · Cited by 148
“PGT151 is another alternative purification reagent that is sensitive to the quaternary integrity of the Env trimers (115).”
BackgroundInfluentialSelf-citationZhu, J., Ofek, G., Yang, Y., Zhang, B., Louder, M. K., Lu, G., McKee, K., Pancera, M., Skinner, J., Zhang, Z., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219320110 · Cited by 135
“The clonally related PGT141–145 recognize an N-linked glycan at residue 160 in the V1/V2 region of the HIV-1 gp120 envelope glycoprotein, with residues in strand C of V1/V2 contributing important contacts (28, 29).”
BackgroundSelf-citationAntibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env
Guttman, M., Cupo, A., Julien, J., Sanders, R. W., Wilson, I. A., Moore, J. P., & Lee, K. K. (2015) · Nature Communications · doi:10.1038/ncomms7144 · Cited by 149
“These residues are known to be proximal to the PG9 epitope, which is centered on the N160 glycan in the crystal structure between PG9 and a V1/V2 scaffold 31 .”
Self-citationStamatatos, L., Pancera, M., & McGuire, A. T. (2017) · Immunological Reviews · doi:10.1111/imr.12483 · Cited by 134
Self-citationBroadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env
Scharf, L., Wang, H., Gao, H., Chen, S., McDowall, A. W., & Bjorkman, P. J. (2015) · Cell · doi:10.1016/j.cell.2015.08.035 · Cited by 132
“Rather than penetrating the glycan shield of HIV-1 Envwith only a single loop, a strategy employed by Abs such as PG9 and PGT128 (McLellan et al., 2011; Pejchal et al., 2011), 8ANC195 inserts its entire variable region into a gap in the Env trimer glycan shield at the interface of gp120 and gp41.”
BackgroundWang, H., Cohen, A. A., Galimidi, R. P., Gristick, H. B., Jensen, G. J., & Bjorkman, P. J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615939113 · Cited by 133
“(A) V1V2 folding topologies in V1V2 scaffold (PDB ID code 5ESV) (32, 33), closed BG505 trimer (PDB ID code 5FYJ) (10, 19), and molecular dynamics model of repositioned V1V2 in full-length CD4-bound gp120 (21).”
BackgroundMethodHIV broadly neutralizing antibody targets
Wibmer, C. K., Moore, P. L., & Morris, L. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000153 · Cited by 147
“It is therefore highly conserved, and antibodies 4E10 and 10E8 are some of the broadest yet identified [8,46]. bNAbs targeting the MPER often interact with the viral membrane via long CDR-H3 loops, which may promote higher than normal levels of autoreactivity for these types of antibodies [47].”
BackgroundInfluentialPriddy, F. H., Lewis, D. J. M., Gelderblom, H. C., Hassanin, H., Streatfield, C., LaBranche, C., Hare, J., Cox, J. H., Dally, L., Bendel, D., et al. (2019) · The Lancet HIV · doi:10.1016/s2352-3018(19)30003-7 · Cited by 131
Kong, R., Louder, M. K., Wagh, K., Bailer, R. T., deCamp, A. C., Greene, K., Gao, H., Taft, J. D., Gazumyan, A., Liu, C., et al. (2014) · Journal of Virology · doi:10.1128/jvi.03136-14 · Cited by 140
Self-citationStructural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers
Pritchard, L. K., Vasiljević, S., Ozorowski, G., Seabright, G. E., Cupo, A., Ringe, R. P., Kim, H. J., Sanders, R. W., Doores, K. J., Burton, D. R., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.05.017 · Cited by 140
“…many potent bNAbs are glycan reactive (Blattner et al., 2014; Falkowska et al., 2014; Garces et al., 2014; Huang et al., 2014; Kong et al., 2013; McLellan et al., 2011; Mouquet et al., 2012; Pancera et al., 2013; Pejchal et al., 2011; Sanders et al., 2002; Scanlan et al., 2002; Scharf et al.,…”
InfluentialSelf-citationThe HIV glycan shield as a target for broadly neutralizing antibodies
Doores, K. J. (2015) · FEBS Journal · doi:10.1111/febs.13530 · Cited by 156
Pritchard, L. K., Spencer, D. I. R., Royle, L., Bonomelli, C., Seabright, G. E., Behrens, A.-J., Kulp, D. W., Menis, S., Krumm, S. A., Dunlop, D. C., et al. (2015) · Nature Communications · doi:10.1038/ncomms8479 · Cited by 125
Self-citationComputational epitope map of SARS-CoV-2 spike protein
Sikora, M., von Bülow, S., Blanc, F. E. C., Gecht, M., Covino, R., & Hummer, G. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008790 · Cited by 146
“Moreover, glycans themselves can be part of epitopes in SARS-CoV-2 S [16, 26] and HIV-1 Env [46].”
BackgroundModular synthesis of N-glycans and arrays for the hetero-ligand binding analysis of HIV antibodies
Shivatare, S. S., Chang, S., Tsai, T.-I., Tseng, S. Y., Shivatare, V. S., Lin, Y., Cheng, Y., Ren, C., Lee, C.-C. D., Pawar, S., et al. (2016) · Nature Chemistry · doi:10.1038/nchem.2463 · Cited by 127
Self-citationvon Bredow, B., Arias, J. F., Heyer, L. N., Moldt, B., Le, K. M., Robinson, J. E., Zolla‐Pazner, S., Burton, D. R., & Evans, D. T. (2016) · Journal of Virology · doi:10.1128/jvi.00347-16 · Cited by 135
Self-citationPing, L., Joseph, S., Anderson, J. A., Abrahams, M.-R., Salazar-Gonzalez, J. F., Kincer, L. P., Treurnicht, F. K., Arney, L., Ojeda, S., Zhang, M., et al. (2013) · Journal of Virology · doi:10.1128/jvi.03577-12 · Cited by 154
“Finally, the newly described four-stranded -sheet that provides a scaffold for the V1 and V2 surface loops is covered with four glycans (positions 130, 156, 160, and 197) (74).”
BackgroundSelf-citationVaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention
Stephenson, K. E., Wagh, K., Korber, B., & Barouch, D. H. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-080219-023629 · Cited by 125
Broadly neutralizing antibodies against HIV-1: Templates for a vaccine
van Gils, M. J., & Sanders, R. W. (2012) · Virology · doi:10.1016/j.virol.2012.10.004 · Cited by 125
“…‘hammerhead’ structure of the HCDR3 gives the PG9 and PG16 antibodies the ability to bind both the two glycans attached to residues N156 (or N173 in some strains) and N160, as well as the underlying protein surface (residues 165–171), resulting in high breadth and potency (McLellan et al., 2011).”
BackgroundInsights into the trimeric HIV-1 envelope glycoprotein structure
Ward, A. B., & Wilson, I. A. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.12.006 · Cited by 130
“Crystal structures of the PG9 and PG16 antibodies in complex with V1 and V2, engineered onto a protein scaffold (34, 39), revealed that the epitope at the trimer apex consists of both high mannose and complex glycans.”
BackgroundSelf-citationAntibody B cell responses in HIV-1 infection
Mouquet, H. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.08.007 · Cited by 145
Hobson‐Peters, J., Harrison, J. J., Watterson, D., Hazlewood, J. E., Vet, L. J., Newton, N. D., Warrilow, D., Colmant, A. M. G., Taylor, C. T., Huang, B., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax7888 · Cited by 115
Wang, W., Nie, J., Prochnow, C., Truong, C., Jia, Z., Wang, S., Chen, X. S., & Wang, Y. (2013) · Retrovirology · doi:10.1186/1742-4690-10-14 · Cited by 114
“Crystal structures of gp120 reveal that these regions can be organized into four structural domains: the inner and outer domains, a 4-stranded bridging sheet, and the V1/V2 domain that has been determined recently [7,8].”
InfluentialCD4-Induced Activation in a Soluble HIV-1 Env Trimer
Guttman, M., Garcia, N. K., Cupo, A., Matsui, T., Julien, J., Sanders, R. W., Wilson, I. A., Moore, J. P., & Lee, K. K. (2014) · Structure · doi:10.1016/j.str.2014.05.001 · Cited by 123
“…have a high degree of HDX protection, which is consistent with the extensive β-sheet secondary structure present in the Greek key motif seen in the PG9-bound scaffolded V1/V2 structure (McLellan et al., 2011) and in the SOSIP.664 trimer structures (Julien et al., 2013a; Lyumkis et al., 2013).”
BackgroundResultSelf-citationNonneutralizing Functional Antibodies: a New “Old” Paradigm for HIV Vaccines
Excler, J.-L., Ake, J., Robb, M. L., Kim, J. H., & Plotkin, S. A. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00230-14 · Cited by 114
Strategies to guide the antibody affinity maturation process
Doria‐Rose, N. A., & Joyce, M. G. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.04.002 · Cited by 136
“broadly neutralizing antibodies, including those that target recently discovered quaternary epitopes [6 ,25,60,61], but show little or no binding to non-neutralizing antibodies such as those targeting the V3 loop [58 ].”
BackgroundMolecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer
Mao, Y., Wang, L., Gu, C., Herschhorn, A., Désormeaux, A., Finzi, A., Xiang, S.-H., & Sodroski, J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307382110 · Cited by 141
Self-citationLandais, E., Murrell, B., Briney, B. S., Murrell, S., Rantalainen, K. I., Berndsen, Z. T., Ramos, A. G., Wickramasinghe, L., Smith, M. L., Eren, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.002 · Cited by 107
“Tyrosine sulfation is also important for binding of bnAbs of this class (McLellan et al., 2011; Sok et al., 2014).”
BackgroundSelf-citationSynthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies
Amin, M. N., McLellan, J. S., Huang, W., Orwenyo, J., Burton, D. R., Koff, W. C., Kwong, P. D., & Wang, L. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1288 · Cited by 115
“For detection of PG16, the ZM-GP6 (EC 50 = 0.22 µg/mL) was more sensitive (15-fold) than the scaffolded ZM109 V1V2 (EC 50 = 3.4 µg/mL), while the CAP-GP6 (EC 50 = 20 µg/mL) was about 2-fold less sensitive than the scaffolded CAP45 V1V2 domain (EC 50 = 9.1 µg/mL) 13 .”
InfluentialSelf-citationThe Secret Life of Viral Entry Glycoproteins: Moonlighting in Immune Evasion
Cook, J. D., & Lee, J. E. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003258 · Cited by 107
“[7, 51] Direct innate immunity antagonism HIV-2 env-encoded glycoprotein counteracts BST-2-mediated viral tethering.”
BackgroundDingens, A. S., Arenz, D., Weight, H., Overbaugh, J., & Bloom, J. D. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.017 · Cited by 109
“For both antibodies, prior studies suggest that binding is driven by electrostatic interactions with positively charged Env residues (Lee et al., 2017; McLellan et al., 2011;Wang et al., 2017).”
Protein and Glycan Mimicry in HIV Vaccine Design
Seabright, G. E., Doores, K. J., Burton, D. R., & Crispin, M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.04.016 · Cited by 115
Self-citationQuaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer
Liu, Q., Acharya, P., Dolan, M. A., Zhang, P., Guzzo, C., Lu, J., Kwon, A. L., Gururani, D., Miao, H., Bylund, T., et al. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3382 · Cited by 105
Self-citationLindesmith, L. C., McDaniel, J. R., Changela, A., Verardi, R., Kerr, S. A., Costantini, V., Brewer-Jensen, P. D., Mallory, M. L., Voss, W. N., Boutz, D. R., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.05.007 · Cited by 113
“Antibodies A1227 and A1431 were produced as previously described (McLellan et al., 2011).”
MethodSelf-citationMirschberger, C., Schiller, C., Schräml, M., Dimoudis, N., Friess, T., Gerdes, C. A., Reiff, U., Lifke, V., Hoelzlwimmer, G., Kolm, I., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0099 · Cited by 114
Go, E. P., Herschhorn, A., Gu, C., Castillo-Menendez, L. R., Zhang, S., Mao, Y., Chen, H., Ding, H., Wakefield, J., Hua, D., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00628-15 · Cited by 111
Recent strategies targeting HIV glycans in vaccine design
Horiya, S., MacPherson, I. S., & Krauss, I. J. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1685 · Cited by 108
Advances in antiviral vaccine development
Graham, B. S. (2013) · Immunological Reviews · doi:10.1111/imr.12098 · Cited by 101
“Human monoclonal antibodies have now been obtained for the four known antigenic sites on HIV gp160 associated with broad neutralization (41, 55–57), and the structures of the antibody interacting with the antigenic sites have been solved (26, 55, 57, 58).”
BackgroundVaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models
Saunders, K. O., Verkoczy, L. K., Jiang, C., Zhang, J., Parks, R., Chen, H., Housman, M., Bouton-Verville, H., Shen, X., Trama, A. M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.12.028 · Cited by 100
“For V1V2 glycan bnAb responses, long HCDR3 are required for neutralization (McLellan et al., 2011; Pancera et al., 2010).”
BackgroundSelf-citationGuenaga, J., de Val, N., Tran, K., Feng, Y., Satchwell, K., Ward, A. B., & Wyatt, R. T. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004570 · Cited by 99
Self-citationCompleteness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth
Wagh, K., Kreider, E. F., Li, Y., Barbian, H. J., Learn, G. H., Giorgi, E. E., Hraber, P., Decker, T., Smith, A. G., Gondim, M. V. P., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.087 · Cited by 114
“Each bNAb class interacts with both protein and glycans (Andrabi et al., 2015; Gorman et al., 2016; Lee et al., 2016; McLellan et al., 2011; Sok et al., 2014; Stewart-Jones et al., 2016).”
Self-citationEvolution of phage display libraries for therapeutic antibody discovery
Zhang, Y. (2023) · mAbs · doi:10.1080/19420862.2023.2213793 · Cited by 113
“171,172 Interestingly, antibodies from some species, such as cow and camelid, are unusual in having a natural elongated CDRH3 (e.g., up to 70 amino acids for cow), which provides extra diversity and paratope complexity.”
BackgroundStewart-Jones, G. B. E., Chuang, G.-Y., Xu, K., Zhou, T., Acharya, P., Tsybovsky, Y., Ou, L., Zhang, B., Fernandez-Rodriguez, B., Gilardi, V., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811980115 · Cited by 97
Self-citationAlam, S. M., Liao, H., Tomaras, G. D., Bonsignori, M., Tsao, C.-Y., Hwang, K., Chen, H., Lloyd, K. E., Bowman, C. M., Sutherland, L. L., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00718-12 · Cited by 97
Self-citationStructural insights into key sites of vulnerability on HIV‐1 Env and influenza HA
Julien, J., Lee, P. S., & Wilson, I. A. (2012) · Immunological Reviews · doi:10.1111/imr.12005 · Cited by 97
“Interestingly, other V1/ V2 recognizing bnAbs for which unliganded crystal structures are also reported in this study (CH04 and PGT145) show similar extended anionic HCDR3 loops capable of penetrating the glycan shield (17).”
BackgroundMethodResultInfluentialSelf-citationShivatare, S. S., Chang, S., Tsai, T.-I., Ren, C., Chuang, H.-Y., Hsu, L. J., Lin, C.-W., Li, S., Wu, C., & Wong, C. (2013) · Journal of the American Chemical Society · doi:10.1021/ja409097c · Cited by 104
Progress in HIV-1 vaccine development
Haynes, B. F., Moody, M. A., Alam, M. S., Bonsignori, M., Verkoczy, L. K., Ferrari, G., Gao, F., Tomaras, G. D., Liao, H., & Kelsoe, G. H. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.04.025 · Cited by 104
Self-citationAntibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike
Lee, J. H., Leaman, D. P., Kim, A. S., de la Peña, A. T., Sliepen, K., Yasmeen, A., Derking, R., Ramos, A. G., de Taeye, S. W., Ozorowski, G., et al. (2015) · Nature Communications · doi:10.1038/ncomms9167 · Cited by 111
“These sites include the receptor, or CD4, binding site (CD4bs) 3,4 , the quaternary epitope surrounding the N160 glycan at the apex of the trimer 1,6,12,13 , the high-mannose patch on the outer domain of gp120 that includes the N332 glycan at the base of variable loop 3 (V3) 1,14–16 and the…”
Self-citationGilbert, P. B., Juraska, M., deCamp, A. C., Karuna, S., Edupuganti, S., Mgodi, N. M., Donnell, D. J., Bentley, C., Sista, N. D., Andrew, P., et al. (2017) · Statistical Communications in Infectious Diseases · doi:10.1515/scid-2016-0001 · Cited by 102
“This diagnostic delay would cause a small and expected negligible amount of bias in the analysis of PE (Meier and Gilbert 2005), but its potential for biasing the correlates analysis is greater given the need to estimate VRC01 concentrations near HIV-1 acquisition times.”
Self-citationLessons learned from HIV-1 vaccine trials: new priorities and directions
McMichael, A. J., & Haynes, B. F. (2012) · Nature Immunology · doi:10.1038/ni.2264 · Cited by 103
Self-citationReprogramming the antigen specificity of B cells using genome-editing technologies
Voss, J. E., González-Martín, A., Andrabi, R., Fuller, R. P., Murrell, B., McCoy, L. E., Porter, K., Huang, D., Li, W., Sok, D., et al. (2019) · eLife · doi:10.7554/elife.42995 · Cited by 99
Self-citationGlobal site-specific analysis of glycoprotein N-glycan processing
Cao, L., Diedrich, J. K., Ma, Y., Wang, N., Pauthner, M., Park, S.-K. R., Delahunty, C. M., McLellan, J. S., Burton, D. R., Yates, J. R., et al. (2018) · Nature Protocols · doi:10.1038/nprot.2018.024 · Cited by 91
“Interestingly, the highmannose and complex-type glycans identified at each glycosylation site of BG505 SOSIP.664 matched the pathway of N-glycan processing, in which high-mannose structures are first trimmed from Man 9 to Man 5 before addition of the terminal monosaccharides that define complex-type/hybrid glycans, as…”
ResultSelf-citationMartinez-Murillo, P., Tran, K., Guenaga, J., Lindgren, G., Ádori, M., Feng, Y., Phad, G. E., Bernat, N. V., Bale, S., Ingale, J., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.04.021 · Cited by 101
“The immunogenic properties of the V2 region were also shown by the isolation of glycan-dependent V2-targeting bNAbs from chronic infected individuals (McLellan et al., 2011; Walker et al., 2009) and isolation of monoclonal antibodies with ADCC activity from RV144 clinical trial vaccine recipients (CH58 and CH59) (Liao…”
BackgroundSelf-citationHIV-1 envelope glycoprotein structure
Merk, A., & Subramaniam, S. (2013) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2013.03.007 · Cited by 89
“The V1V2 loop, expressed in the context of a non-HIV scaffold or as a 19-mer peptide, has been crystallized in complex with three Fabs, with three disparate conformations for V1V2 in each of these complexes [26,27].”
BackgroundImpact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies
Hraber, P., Korber, B., Lapedes, A. S., Bailer, R. T., Seaman, M. S., Gao, H., Greene, K., McCutchan, F. E., Williamson, C. E., Kim, J. H., et al. (2014) · Journal of Virology · doi:10.1128/jvi.01705-14 · Cited by 104
“We also combined V1 and V2 (V1V2) 423 hypervariable regions for analyses, because they are spatially juxtaposed and surround regions known to 424 contain critical epitopes for PG9-like bnAbs (85, 86).”
BackgroundSelf-citationTwo-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens
Georgiev, I. S., Joyce, M. G., Chen, R. E., Leung, K., McKee, K., Druz, A., Galen, J. G. V., Kanekiyo, M., Tsybovsky, Y., Yang, E. S., et al. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00192 · Cited by 91
Self-citationStructural basis for the neutralization of hepatitis E virus by a cross-genotype antibody
Gu, Y., Tang, X., Zhang, X., Song, C., Zheng, M., Wang, K., Zhang, J., Ng, M., Hew, C., Li, S., et al. (2015) · Cell Research · doi:10.1038/cr.2015.34 · Cited by 94
Lee, J. H., de Val, N., Lyumkis, D., & Ward, A. C. (2015) · Structure · doi:10.1016/j.str.2015.07.020 · Cited by 92
“Indeed, structures of the majority of glycans on Env larger than the core trisaccharide have been determined in this manner (Garces et al., 2014; Julien et al., 2013a; Julien et al., 2013c; Kong et al., 2013; McLellan et al., 2011; Pejchal et al., 2011), as the glycans not interacting with antibodies are disordered, o…”
BackgroundSelf-citationBroadly Neutralizing Antibodies for HIV Eradication
Stephenson, K. E., & Barouch, D. H. (2016) · Current HIV/AIDS Reports · doi:10.1007/s11904-016-0299-7 · Cited by 89
“Analysis of similar antibodies in this class revealed that the long heavy-chain CDR region 3 loops pierce the HIV-1 glycan shield to bind to the quaternary epitope at the apex of the HIV-1 spike where the V1V2 regions of two gp120 protomers meet [42, 43].”
BackgroundWang, H., Barnes, C. O., Yang, Z., Nussenzweig, M. C., & Bjorkman, P. J. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.09.003 · Cited by 90
“Structure of Displaced V1V2 The V1V2 region comprises a twisted 5-strand b sheet (strands A–D and a V2 strand) with mostly disordered connecting loops in monomeric epitope scaffolds (Gorman et al., 2016; McLellan et al., 2011; Pan et al., 2015; Pancera et al., 2013), closed Envs (Ward andWilson, 2017), and the b12-bou…”
BackgroundSelf-citationZhu, J., Wu, X., Zhang, B., McKee, K., O’Dell, S., Soto, C., Zhou, T., Casazza, J. P., Program, N. C. S., Mullikin, J. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306262110 · Cited by 87
Self-citationChuang, G., Zhou, J., Acharya, P., Rawi, R., Shen, C., Sheng, Z., Zhang, B., Zhou, T., Bailer, R. T., Dandey, V. P., et al. (2018) · Structure · doi:10.1016/j.str.2018.10.007 · Cited by 90
“For example, structures of PG9 with scaffolded V1V2 regions of Env (McLellan et al., 2011) and also with Env trimer (Julien et al.”
BackgroundMethodInfluentialSelf-citationTargeting host-derived glycans on enveloped viruses for antibody-based vaccine design
Crispin, M., & Doores, K. J. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.02.002 · Cited by 94
McCoy, L. E., Falkowska, E., Doores, K. J., Le, K. M., Sok, D., van Gils, M. J., Euler, Z., Burger, J. A., Seaman, M. S., Sanders, R. W., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005110 · Cited by 90
“We have previously shown that, for a minority of isolates, both PG9 and PG16 have neutralization curves that reach 100% and non-sigmoidal slopes (Walker, 2009) [14].”
BackgroundInfluentialSelf-citationStructural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen
Kong, L., Lee, D. E., Kadam, R. U., Liu, T., Giang, E., Nieusma, T., Garcés, F., Tzarum, N., Woods, V. L., Ward, A. B., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609780113 · Cited by 85
“Assuming that HCV1 primarily interacts with E2 via AS412, flexibility at AS412 should translate to larger, rigid-body motions for HCV1, as previously observed for anti–HIV-1 bNAb PG9 when bound to HIV-1 envelope glycoprotein gp120 as a monomer (34).”
Self-citationLiao, H., Tsao, C.-Y., Alam, S. M., Muldoon, M. R., Vandergrift, N., Ma, B.-J., Lu, X., Sutherland, L. L., Scearce, R. M., Bowman, C. M., et al. (2013) · Journal of Virology · doi:10.1128/jvi.02297-12 · Cited by 91
“These epitopes included the epitopes recognized by the bNAbs 2F5 (65), 4E10 (66), PG9, PG16, and VRC01 (57) and the glycan bNAb, 2G12 (67), in addition to the PG9 and PG16 (17) V2V3 conformational epitope bNAbs (64), as well as CH01-CH04 MAbs against the same V1/V2 bNAb epitope (68, 69).”
BackgroundSelf-citationPace, C. S., Song, R., Ochsenbauer, C., Andrews, C. D., Franco, D., Yu, J., Oren, D. A., Seaman, M. S., & Ho, D. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304985110 · Cited by 86
“4 shows the gp120 trimer (41) together with a superimposition of the known CD4 structure (42) bound by iMab Fab (29), along with the known structure of PG9 scFv (8) connected by a 15-aa linker.”
BackgroundModulation of Glycan Recognition by Clustered Saccharide Patches
(2014) · International Review of Cell and Molecular Biology · doi:10.1016/b978-0-12-800097-7.00003-8 · Cited by 84
Overview of Neutralizing Antibodies and Their Potential in COVID-19
Morales‐Núñez, J. J., Muñóz-Valle, J. F., Torres-Hernández, P. C., & Hernández‐Bello, J. (2021) · Vaccines · doi:10.3390/vaccines9121376 · Cited by 94
“The complementarity determining regions (CDRs) with more mutations are also variables for each type of antibody depending on the virus; as an example, for HIV-1, it has been seen to have a greater effect on CDR H3 [79].”
BackgroundGórny, M. K., Pan, R., Williams, C. A. U., Wang, X., Volsky, B., O'Neal, T., Spurrier, B., Sampson, J. M., Li, L., Seaman, M. S., et al. (2012) · Virology · doi:10.1016/j.virol.2012.02.003 · Cited by 83
“The potential epitope residues for mAb 697 are shown on the surface of the V1V2 structure recently described (McLellan et al., 2011) (Supplementary Fig.”
BackgroundCell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope
Pritchard, L. K., Harvey, D. J., Bonomelli, C., Crispin, M., & Doores, K. J. (2015) · Journal of Virology · doi:10.1128/jvi.01190-15 · Cited by 88
“These bnAbs target three main regions on Env, the N332 glycan (e.g., 2G12, PGT121, PGT128, and PGT135) (3, 4, 16–18), the N160 glycan (e.g., PG9, PGT145, and CH04) (4, 5, 19, 20), and the glycans at the gp120-gp41 interface (e.g., PGT151) (21).”
Keefer, M. C., Gilmour, J. W., Hayes, P., Gill, D. K., Kopycinski, J. T., Cheeseman, H. M., Cashin‐Cox, M., Naarding, M. A., Clark, L., Fernández, N., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041936 · Cited by 92
Go, E. P., Ding, H., Zhang, S., Ringe, R. P., Nicely, N. I., Hua, D., Steinbock, R. T., Golabek, M., Alin, J., Alam, S. M., et al. (2017) · Journal of Virology · doi:10.1128/jvi.02428-16 · Cited by 86
“These bNAbs (PG9, PG16, PGT145, CH01-04, and CAP256) have long, extended CDRH3 regions (39).”
BackgroundSelf-citationChuang, G., Geng, H., Pancera, M., Xu, K. Y., Cheng, C., Acharya, P., Chambers, M. J., Druz, A., Tsybovsky, Y., Wanninger, T. G., et al. (2017) · Journal of Virology · doi:10.1128/jvi.02268-16 · Cited by 83
Self-citationDoria‐Rose, N. A., Georgiev, I. S., O'Dell, S. J., Chuang, G., Staupe, R. P., McLellan, J. S., Gorman, J., Pancera, M., Bonsignori, M., Haynes, B. F., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00696-12 · Cited by 82
“These observations confirm and extend the information gained from the crystal structures of PG9 with scaffolded V1/V2 from strains ZM109 and CAP45 (7).”
BackgroundMethodResultSelf-citationBehrens, A., Harvey, D. J., Milne, E., Cupo, A., Kumar, A., Zitzmann, N., Struwe, W. B., Moore, J. P., & Crispin, M. (2016) · Journal of Virology · doi:10.1128/jvi.01894-16 · Cited by 83
Choi, Y. K., Cao, Y., Frank, M., Woo, H., Park, S., Yeom, M. S., Croll, T. I., Seok, C., & Im, W. (2021) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.0c01144 · Cited by 84
Willis, J. R., Berndsen, Z. T., Krystal, M., Steichen, J. M., Schiffner, T., Landais, E., Liguori, A., Kalyuzhniy, O., Allen, J. D., Baboo, S., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.09.001 · Cited by 79
“HCDR3s for these bnAbs mediate binding by reaching through the conserved glycan shield to contact a positively charged, semi-conserved protein surface on strand C of the V2 loop (Andrabi et al., 2015, 2017; Gorman et al., 2016; Landais et al., 2017; Lee et al., 2017;McLellan et al., 2011; Pancera et al., 2010, 2013; P…”
BackgroundResultSelf-citationMu, Z., Wiehe, K. J., Saunders, K. O., Henderson, R. C., Cain, D. W., Parks, R., Martik, D., Mansouri, K., Edwards, R. J., Newman, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110514 · Cited by 84
“17DT Env by filling the glycan holes at positions 230and289andby introducing169Kmutation,which is critical to Env interaction with V2-glycan bnAbs (Doria-Rose et al., 2012; Lee et al., 2017; McLellan et al., 2011).”
BackgroundSelf-citationHuman adaptive immune receptor repertoire analysis—Past, present, and future
Nielsen, S. C. A., & Boyd, S. D. (2018) · Immunological Reviews · doi:10.1111/imr.12667 · Cited by 89
Derdeyn, C. A., Moore, P. L., & Morris, L. (2014) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000057 · Cited by 85
“Further studies suggest that the vaccine-elicited mAbs recognize a conformation of V1V2 that is distinct from that recognized by bnAbs [54,55].”
BackgroundCale, E. M., Gorman, J., Radakovich, N. A., Crooks, E. T., Osawa, K., Tong, T., Li, J., Raju, N., Ozorowski, G., Ambrozak, D. R., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.04.011 · Cited by 79
“In contrast, other V1V2 NAb CDRH3 loops are negatively charged due to prevalent Glu and Asp residues and sulfated tyrosines (Figure 4A, 4E and 4F), which interact with the positively charged strand C (Andrabi et al., 2015; Bonsignori et al., 2011; Doria-Rose et al., 2015; Gorman et al., 2016; McLellan et al., 2011; Wa…”
InfluentialSelf-citationA broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry
Herschhorn, A., Gu, C., Espy, N., Richard, J., Finzi, A., & Sodroski, J. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1623 · Cited by 79
“Compounds 18A, 18A-4 (5), 18A-5 (6), 18A-6 (7) and 34A (10) were from Asinex, Moscow, Russia; compounds 18A-1 (2), 18A-2 (3), 18A-3 (4), 614 (25), 615 (26) and 617 (28) were from Enamine, Kiev, Ukraine; compounds 20CB (8), 27CB (9), 600 (11), 601 (12), 602 (13), 603 (14), 604 (15), 605 (16), 606 (17), 607 (18), 608 (1…”
Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies
Schiffner, T., Sattentau, Q. J., & Duncan, C. J. A. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.10.020 · Cited by 104
Saunders, K. O., Nicely, N. I., Wiehe, K. J., Bonsignori, M., Meyerhoff, R. R., Parks, R., Walkowicz, W. E., Aussedat, B., Wu, N. R., Cai, F., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.003 · Cited by 80
“Most gp120 bnAb epitopes include contacts with glycans (Blattner et al., 2014; Doria-Rose et al., 2014; Garces et al., 2014; Kong et al., 2013;McLellan et al., 2011; Pancera et al., 2014; Pejchal et al., 2011; Zhou et al., 2013), yet Env glycans in the setting of vaccination are poorly immunogenic…”
Self-citationDoria‐Rose, N. A., Louder, M. K., Yang, Z., O'Dell, S. J., Nason, M., Schmidt, S. D., McKee, K., Seaman, M. S., Bailer, R. T., & Mascola, J. R. (2012) · Journal of Virology · doi:10.1128/jvi.06745-11 · Cited by 86
“We stratified the HIV-1 isolates into VRC01 neutralization-resistant and neutralization-sensitive categories and observed no significant differences in the IC50s of PG9 and PG16 against viruses in those categories (Fig.”
BackgroundInfluentialSelf-citationClonal redemption and clonal anergy as mechanisms to balance B cell tolerance and immunity
Burnett, D. L., Reed, J. H., Christ, D., & Goodnow, C. C. (2019) · Immunological Reviews · doi:10.1111/imr.12808 · Cited by 81
Zhou, T., Zheng, A., Baxa, U., Chuang, G., Georgiev, I. S., Kong, R., O'Dell, S. J., Shahzad‐ul‐Hussan, S., Shen, C., Tsybovsky, Y., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.02.013 · Cited by 87
“Overall, the recognition and neutralization by VRC-PG05 requiring two glycans and a small protein surface of HIV-1 Env was reminiscent of other HIV-1-neutralizing antibodies with glycopeptide epitopes that pierce the HIV-1 glycan shield (Blattner et al., 2014; Julien et al., 2013; Kong et al., 2013, 2016; McLellan et…”
InfluentialSelf-citationMarchetti, R., Pérez, S., Ardá, A., Imberty, A., Jiménez‐Barbero, J., Silipo, A., & Molinaro, A. (2016) · ChemistryOpen · doi:10.1002/open.201600024 · Cited by 89
Gorman, J., Chuang, G., Lai, Y., Shen, C., Boyington, J. C., Druz, A., Geng, H., Louder, M. K., McKee, K., Rawi, R., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.052 · Cited by 75
Self-citationMorphology and ultrastructure of retrovirus particles
Zhang, W., 1 Institute for Molecular Virology, U. O. M., Cao, S., L. Martin, J., D. Mueller, J., & M. Mansky, L. (2015) · AIMS Biophysics · doi:10.3934/biophy.2015.3.343 · Cited by 74
Metadata
- Authors
- McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., O’Dell, S., Patel, N., Shahzad-ul-Hussan, S., Yang, Y., Zhang, B., Zhou, T., Zhu, J., Boyington, J. C., Chuang, G.-Y., Diwanji, D., Georgiev, I., Do Kwon, Y., Lee, D., Louder, M. K., Moquin, S., Schmidt, S. D., Yang, Z.-Y., Bonsignori, M., Crump, J. A., Kapiga, S. H., Sam, N. E., Haynes, B. F., Burton, D. R., Koff, W. C., Walker, L. M., Phogat, S., Wyatt, R., Orwenyo, J., Wang, L.-X., Arthos, J., Bewley, C. A., Mascola, J. R., Nabel, G. J., Schief, W. R., Ward, A. B., Wilson, I. A., & Kwong, P. D.
- Affiliations
- National Institutes of Health (US)
- University of Washington (US)
- Scripps Research Institute (US)
- Duke University (US)
- Tumaini University (TZ)
- International AIDS Vaccine Initiative (US)
- University of Maryland, Baltimore (US)
- Corresponding author
- Kwong, Peter D.
- ORCID
- McLellan, Jason S.
- Pancera, Marie
- Carrico, Chris
- Gorman, Jason
- Julien, Jean-Philippe
- Khayat, Reza
- Louder, Robert
- Patel, Nikita
- Yang, Yongping
- Zhang, Baoshan
- Zhou, Tongqing
- Zhu, Jiang
- Boyington, Jeffrey C.
- Chuang, Gwo-Yu
- Diwanji, Devan
- Georgiev, Ivelin
- Louder, Mark K.
- Moquin, Stephanie
- Schmidt, Stephen D.
- Bonsignori, Mattia
- Crump, John A.
- Kapiga, Saidi H.
- Haynes, Barton F.
- Burton, Dennis R.
- Koff, Wayne C.
- Walker, Laura M.
- Wyatt, Richard
- Wang, Lai-Xi
- Arthos, James
- Bewley, Carole A.
- Mascola, John R.
- Nabel, Gary J.
- Schief, William R.
- Ward, Andrew B.
- Wilson, Ian A.
- Kwong, Peter D.
- Venue
- Nature
- Published
- 2011-11-23
- Volume
- 480
- Issue
- 7377
- Pages
- 336-343
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3406929
- OpenAlex
- W2122617162
- Cited by
- 830
- References
- 69
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 23 · 2023: 25 · 2022: 36 · 2021: 38 · 2020: 39 · 2019: 52 · 2018: 63 · 2017: 70 · 2016: 64 · 2015: 84 · 2014: 92 · 2013: 120 · 2012: 78
- FWCI
- 36.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DukeSpace (Duke University) (submittedVersion, cc-by-nc-nd)
- Funders
- U.S. Department of Energy (W - 31 - 109 - Eng - 38)
- International AIDS Vaccine Initiative
- Ragon Institute of MGH, MIT and Harvard
- National Institutes of Health
- Office of Science (W-31-109-ENG-38)
- Canadian Institutes of Health Research
- National Institute of Allergy and Infectious Diseases (R01AI033292, R01AI084817)
- National Center for Research Resources (RR017573, P41RR017573)
- Basic Energy Sciences (W-31-109-Eng38)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- HIV-1 gp120, antibody-antigen complex structure, N-glycosylation, carbohydrate recognition, HIV vaccine development, envelope glycoprotein
- MeSH terms
- Amino Acid Sequence, Antibody Affinity, Antibody Specificity, Antigen-Antibody Complex, Epitopes, Binding Sites, Antibody, Glycopeptides, Glycosylation, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Polysaccharides, HIV Antibodies, HIV-1, HIV Envelope Protein gp120, AIDS Vaccines, Conserved Sequence, Protein Structure, Tertiary, Crystallography, X-Ray, Amino Acid Motifs, Protein Structure, Quaternary, Immune Evasion, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.